Search

Displaying results 6911 - 6920 of 10000 in total
  1. Drug

    GC-373

    go.drugbank.com/drugs/DB15797
    Experimental

    It is an inhibitor of M<sup>pro</sup> (otherwise known as 3CL<sup>pro</sup>), a viral encoded protease that cleaves and activates functional proteins involved in viral replication and transcription[A219036 … Along with its prodrug, GC-376, GC-373 was recently investigated _in vitro_ in cell culture against SARS-Cov-2 M<sup>pro</sup> [A219036].

  2. Drug

    Lucatumumab

    go.drugbank.com/drugs/DB06360
    Investigational

  3. Drug

    Telatinib

    go.drugbank.com/drugs/DB15393
    Investigational

    Telatinib is under investigation in clinical trial NCT03817411 (Telatinib in Combination With Capecitabine/ Oxaliplatin in 1st Line Gastric or GEJ Cancer).

  4. Drug

    Chiauranib

    go.drugbank.com/drugs/DB16124
    Investigational

    Chiauranib is under investigation in clinical trial NCT03974243 (Chiauranib in Combination With Chidamide in Patients With Relapsed/refractory Non-hodgkin's Lymphoma).

  5. Drug

    DFV890

    go.drugbank.com/drugs/DB16461
    Investigational

    DFV890 is under investigation in multiple clinical trials for its efficacy, safety, and tolerability across various conditions: NCT06031844 (coronary heart disease with elevated hsCRP), NCT04886258 (symptomatic

  6. Drug

    Xaliproden

    go.drugbank.com/drugs/DB06393
    Investigational

  7. Drug

    Anpocogin

    go.drugbank.com/drugs/DB06552
    Investigational

    Recombinant nematode anticoagulant protein c2 (rNAPc2) is a specific inhibitor of tissue factor (TF)/factor VIIa complex with novel antithrombotic activity. [A175642]

  8. Drug

    Rusalatide

    go.drugbank.com/drugs/DB05309
    Investigational

    TP508 is a non-proteolytic synthetic peptide representing the portion of human thrombin originally identified as the fibroblast high-affinity receptor binding domain.

  9. Drug

    Perifosine

    go.drugbank.com/drugs/DB06641
    Investigational

    Perifosine is a novel alkylphospholipid with antiproliferative properties attributed to protein kinase B inhibition.

  10. Drug

    Viralym-C

    go.drugbank.com/drugs/DB17975
    Investigational

    It was granted FDA orphan designation in January 2017 and investigated for the treatment of CMV infection.[A260291, L47241] … Viralym-C is an investigational T-cell immunotherapy developed by ViraCyte. It consists of Human Leukocyte Antigen (HLA)-matched cytomegalovirus (CMV)-specific T lymphocytes.